Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Tel 617-252-7500

November 30, 2009

Name
Address Line 1
Address Line 2
City, State Zip

RE: Important Update Regarding New Supply of Fabrazyme® (agalsidase beta for injection)

Dear Doctor,

We are writing to update you on the availability of Fabrazyme® (agalsidase beta) during the first quarter of 2010. As you are aware, beginning on October 1, 2009, Genzyme instituted a reduction in shipments of Fabrazyme to approximately 30% of forecasted demand in order to manage supply during the current product shortage. This shortage resulted from the suspension of production at our Allston Landing manufacturing facility while Genzyme completed a comprehensive sanitation process.

As we have previously communicated, that process is now complete, and bioreactors used to produce Fabrazyme have been fully operational since August. However, due to the temporary interruption of fill/finish operations for maintenance at Allston and ongoing low manufacturing productivity **Genzyme will continue shipping Fabrazyme® at the current 30% level through the first quarter of 2010**.

Genzyme plans to resume shipping Fabrazyme at 70 – 100% of full dose for existing patients beginning in the second quarter 2010. The range and timing depends on restarting fill/finish for Fabrazyme at the Allston facility and on restoring the overall productivity of Fabrazyme manufacturing.

- Genzyme plans to resume fill/finish of Fabrazyme at Allston in late December, which will enable Fabrazyme shipping at 70 – 100% of full dose in beginning in April, 2010.

- Genzyme plans to sustain supply of Fabrazyme in this range at current manufacturing levels. Genzyme anticipates that overall manufacturing productivity will be sufficient to support growth in the number of Fabrazyme-treated patients in the second half of 2010.

Genzyme will have more information and will communicate further details about Fabrazyme supply in February 2010, including about when supply of Fabrazyme is sufficient to accommodate new patients.

Currently, the 30% level of supply is being achieved by shipping each patient two full (1 mg/kg) doses over the last 14 weeks of 2009, which can be administered as determined by each physician and patient within the restraints of fixed vial sizes. The US Fabrazyme Stakeholder Working Group developed guidelines to assist physicians in spreading out the two-dose allotment to minimize time between infusions (see attached). This approach may need to be repeated in the first three months of 2010, but Genzyme is exploring the possibility of increasing the ratio of 5 mg to 35 mg vials in order to allow more flexibility with dosing regimens. Genzyme will inform you about this option in the coming weeks.

For more information, health care providers and patients should contact their Genzyme Case Manager to coordinate all orders for Fabrazyme, insurance or billing issues, or infusion agency questions and contact Genzyme Medical Affairs at 1-800-745-4447, option 2.

Patients will be notified of the continuation of the reduced supply via a letter later this week.

Genzyme recognizes the significant challenges that the limited availability of Fabrazyme has created for patients and caregivers, and we appreciate all that you have done throughout the year to help patients manage through this disruption. We are working diligently to improve our ability to supply the long-term needs of patients with Fabry disease.

On behalf of everyone at Genzyme, thank you for your continued understanding and support.

Sincerely,

Daniel Gruskin, MD
Senior Director, Global Medical Affairs
Genzyme